Providence launches groundbreaking study to elevate real-world use of multi-cancer early detection

• Providence Genomics and Providence-Swedish Cancer Institute have launched the PREVAIL study, “Providence Evaluation of Annual Cancer Screenings” to understand the ways that individuals with a genetic predisposition to cancer access innovative screening tools and how access may impact their choices and care. These screening tools include access to specialized imaging and novel blood tests for cancer detection, including the Galleri test by GRAIL and others.  

• The multi-year mixed methods study will follow enrolled participants for three years. Data collection includes participant surveys, interviews, and analysis of electronic health records. Recruitment for the study is ongoing in Providence Swedish, Washington, and California.

‍